These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Patient tolerance to carbonic anhydrase inhibitors. Lichter PR; Newman LP; Wheeler NC; Beall OV Am J Ophthalmol; 1978 Apr; 85(4):495-502. PubMed ID: 655230 [TBL] [Abstract][Full Text] [Related]
5. Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. Cowan RA; Hartnell GG; Lowdell CP; Baird IM; Leak AM Br Med J (Clin Res Ed); 1984 Aug; 289(6441):347-8. PubMed ID: 6432091 [TBL] [Abstract][Full Text] [Related]
6. Decreased libido--a side effect of carbonic anhydrase inhibitor. Wallace TR; Fraunfelder FT; Petursson GJ; Epstein DL Ann Ophthalmol; 1979 Oct; 11(10):1563-6. PubMed ID: 555849 [TBL] [Abstract][Full Text] [Related]
7. MK-927: a topically effective carbonic anhydrase inhibitor in patients. Bron AM; Lippa EA; Hofmann HM; Feicht BI; Royer JG; Brunner-Ferber FL; Panebianco DL; Von Denffer HA Arch Ophthalmol; 1989 Aug; 107(8):1143-6. PubMed ID: 2667509 [TBL] [Abstract][Full Text] [Related]
8. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. Higashihara E; Nutahara K; Takeuchi T; Shoji N; Araie M; Aso Y J Urol; 1991 May; 145(5):942-8. PubMed ID: 2016806 [TBL] [Abstract][Full Text] [Related]
9. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy. Hiett JA; Dockter CA Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242 [TBL] [Abstract][Full Text] [Related]
10. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014 [TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? Block ER; Rostand RA Surv Ophthalmol; 1978; 23(3):169-72. PubMed ID: 734612 [TBL] [Abstract][Full Text] [Related]
12. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects. Nesher R; Ticho U Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130 [TBL] [Abstract][Full Text] [Related]
15. Hypercarbia and acidosis associated with carbonic anhydrase inhibition: a hazard of topical mafenide acetate use in renal failure. Liebman PR; Kennelly MM; Hirsch EF Burns Incl Therm Inj; 1982 Jul; 8(6):395-8. PubMed ID: 6809230 [No Abstract] [Full Text] [Related]
16. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March WF; Ochsner KI Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964 [TBL] [Abstract][Full Text] [Related]
17. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842 [TBL] [Abstract][Full Text] [Related]
18. Short-term use of carbonic anhydrase inhibitors and hematologic side effects. Fraunfelder FT; Fraunfelder FW Arch Ophthalmol; 1992 Apr; 110(4):446-7. PubMed ID: 1562240 [No Abstract] [Full Text] [Related]